Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02073968 : PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Pathologically proven (either histologic or cytologic) diagnosis of NSCLC with any of
the following stages (according to the American Joint Committee on Cancer [AJCC]
Staging Manual, 7th edition):

- Stage IIIA or IIIB

- Stage II NSCLC with medical contraindication to curative surgical resection

- Stage IV disease with solitary brain metastasis that has been treated radically
(eg: with surgical resection or stereotactic radiosurgery) and thoracic disease
that would be classified as stage II-III

- Appropriate diagnostic/staging workup, including:

- Complete history and physical examination

- Whole body PET/computed tomography (CT) scan within 42 days prior to study entry
demonstrating hypermetabolic pulmonary lesion(s) and/or thoracic lymph node(s),
with a maximum standardized uptake volume (SUV) > 6 for at least one lesion; if
PET/CT was obtained more than 42 days prior to study entry and is not repeated,
CT scan of the chest within 28 days prior to study entry demonstrating stable
disease is required

- Magnetic resonance imaging (MRI) of the brain or CT scan of the head with
contrast within 42 days prior to study entry

- Biopsy confirmation of suspected metastatic disease identified by PET/CT is

- Pulmonary function tests (PFTs) within 6 weeks of study entry are highly
recommended but not required

- No prior chemotherapy or thoracic radiotherapy for lung cancer

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Absolute neutrophil count (ANC) >= 1,500 cells/ul

- Platelets >= 100,000 cells/ul

- Hemoglobin >= 9.0 g/dl (Note: the use of transfusion or other intervention to achieve
hemoglobin [Hgb] >= 9.0 g/dl is acceptable)

- Total bilirubin < 3.0 times the institutional upper limit of normal (ULN)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x the ULN

- Serum creatinine =< 1.5 x ULN or calculated creatinine clearance >= 50 ml/min (by
Cockroft-Gault formula)

- Women of childbearing potential must:

- Have a negative serum or urine pregnancy test within 72 hours prior to the start
of study therapy

- Agree to utilize an adequate method of contraception throughout treatment and
for at least 4 weeks after study therapy is completed

- Be advised of the importance of avoiding pregnancy during trial participation
and the potential risks of an unintentional pregnancy

- All patients must sign study specific informed consent prior to study entry

Exclusion Criteria:

- Pleural or pericardial effusion

- A patient with pleural effusion may be enrolled the effusion is sampled by
thoracentesis and cytology is negative or the effusion is seen on axial imaging
but not on chest x-ray and deemed too small to tap under CT or ultrasound

- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
treatment of either a psychiatric or physical (e.g., infectious) illness

- Women who

- Are unwilling or unable to use an acceptable method to avoid pregnancy for the
entire study period and for at least 4 weeks after cessation of study therapy

- Have a positive pregnancy test at baseline

- Are pregnant or breastfeeding

- Poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL) despite
attempts to improve glucose control by fasting duration and adjustment of
medications; patients with diabetes will preferably be scheduled for PET/CT imaging
in the morning, and instructions for fasting and use of medications will be provided
in consultation with the patients' primary physicians
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557